top of page

Summit Therapeutics' Jack West on the company's PD-1xVEGF bi-specific vs Keytruda news

V.P. of Clinical Operations Jack West gives his interpretation of the announcement that Summit's partner Akeso made in China that it beat Keytruda on PFS head-to-head in 1L lung. He shares his opinion of how this data could translate outside of China and what Summit's development plans are currently.



Comentarios


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

bp-logo.png

Breakthrough Properties is a life science real estate company that is exclusively focused on delivering cutting-edge environments for the life science industry. With a portfolio of roughly 5 million square feet across the US, UK and continental Europe, Breakthrough has emerged as a leading partner for high-growth biotechs and pharmas around the world. 

bottom of page